BioWorld® - Medical Device Daily

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information
Polydex Pharmaceuticals Ltd.
421 Comstock Road
Toronto M1L 2H5, Canada
Phone: (416) 755-2231; Fax: (416) 755-0334
Web: www.polydex.com
E-mail: info@polydex.com
KEY PERSONNEL: George G. Usher; Chairman, President and CEO
Sharon Wardlaw; Exec. VP
EMPLOYEES: 28 employees
HISTORY: Founded in 1969
Began biotech R&D in 1974
Acquired Vet Labs of Lenexa, Kan.
Sold Vet Labs in early 2004
FACILITIES: 28,000 sq. ft. Toronto production facility
STOCK-FINANCIAL HISTORY: NASDAQ--POLXF / Boston Stock Exchange--PXL
Sales $5.265M (YE 06) compared to $6.372M (YE 05)
Net loss (YE 06) compared to (YE 05)
Earnings per share (YE 06) compared to $0.38/share
(YE 05)
Average shares outstanding 3.059M (YE 06) compared to 3.042M (YE 05)
PRIVATE PLACEMENTS: American Heritage Fund--1M shares at $1.75/share (12/94)
SUBSIDIARIES/DIVISIONS: Dextran Products Ltd.--Scarboro, ON (see separate entry)
Corporate office:
Polydex Pharmaceuticals Ltd.
Sandringham House
83 Shirley Street
Nassau, Bahamas
Phone: (242) 322-8571
Fax: (242) 328-6919
PRINCIPAL INVESTORS: American Heritage Fund--$2.25M
Continental Grain Co.--$3.6M
BUSINESS STRATEGY: Conduct research related to dextran
AGREEMENTS: Name Products Content of Agreement Date
Canadian
Bacterial Disease
Network
RESEARCH & DEVELOPMENT: Cystic fibrosis therapeutics
Contraceptive gel (cellulose sulfate)
PRODUCTS ON MARKET: Iron dextran (veterinary and human)
Dextran sulfate for hybridoma
Veterinary generics
Dextran research and
licensing
agreements
PRODUCTS IN DEVELOPMENT: Name Status
Dextran for cystic fibrosis in clinicals
Ushercell - contraceptive prophylactic in Phase II/III clinicals
Copyright ©2006 AHC Media ® 320